Hormonal contraceptive use and risk of glioma among younger women: A nationwide case-control study

British Journal of Clinical Pharmacology

Volumn 79, Issue 4, 2015, Pages 677-684

  Andersen, Lene ^a,b   Friis, Søren ^c,d,e   Hallas, Jesper ^f   Ravn, Pernille ^a,b   Kristensen, Bjarne W ^a,b   Gaist, David ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

brain tumour epidemiology; case control study; glioma; hormonal contraceptive; risk

Indexed keywords

ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CONTRACEPTIVE AGENT; ESTROGEN; GESTAGEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ALLERGY; ARTICLE; ASTHMA; ASTROCYTOMA; CANCER RISK; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; FEMALE; GLIOBLASTOMA; GLIOMA; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MIDDLE AGED; OLIGODENDROGLIOMA; PARITY; POPULATION BASED CASE CONTROL STUDY; PREMENOPAUSE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; TREND STUDY; BRAIN NEOPLASMS; CASE CONTROL STUDY; CHEMICALLY INDUCED; ODDS RATIO; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; DENMARK; FEMALE; GLIOMA; HUMANS; MIDDLE AGED; ODDS RATIO; RISK; YOUNG ADULT;

EID: 84925437350     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12535     Document Type: Article

References (42)

1. Lönn S, Klaeboe L, Hall P, Mathiesen T, Auvinen A, Christensen HC, Johansen C, Salminen T, Tynes T, Feychting M,. Incidence trends of adult primary intracerebral tumors in four Nordic countries. Int J Cancer 2004; 108: 450-455.
2. Deltour I, Johansen C, Auvinen A, Feychting M, Klaeboe L, Schuz J,. Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974-2003. J Natl Cancer Inst 2009; 101: 1721-1724.
3. Cowppli-Bony A, Bouvier G, Rué M, Loiseau H, Vital A, Lebailly P, Fabbro-Peray P, Baldi I,. Brain tumors and hormonal factors: review of the epidemiological literature. Cancer Causes Control 2011; 22: 697-714.
4. Qi ZY, Shao C, Zhang X, Hui GZ, Wang Z,. Exogenous and endogenous hormones in relation to glioma in women: a meta-analysis of 11 case-control studies. PLoS ONE 2013; 8: e68695.
5. Hochberg F, Toniolo P, Cole P, Salcman M,. Nonoccupational risk indicators of glioblastoma in adults. J Neurooncol 1990; 8: 55-60.
6. Huang K, Whelan EA, Ruder AM, Ward EM, Deddens JA, Davis-King KE, Carreon T, Waters MA, Butler MA, Calvert GM, Schulte PA, Zivkovich Z, Heineman EF, Mandel JS, Morton RF, Reding DJ, Rosenman KD,. Reproductive factors and risk of glioma in women. Cancer Epidemiol Biomarkers Prev 2004; 13: 1583-1588.
7. Hatch EE, Linet MS, Zhang J, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD,. Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer 2005; 114: 797-805.
8. Silvera SA, Miller AB, Rohan TE,. Hormonal and reproductive factors and risk of glioma: a prospective cohort study. Int J Cancer 2006; 118: 1321-1324.
9. Wigertz A, Lönn S, Mathiesen T, Ahlbom A, Hall P, Feychting M,. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 2006; 164: 629-636.
10. Benson VS, Pirie K, Green J, Casabonne D, Beral V,. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer 2008; 99: 185-190.
11. Felini MJ, Olshan AF, Schroeder JC, Carozza SE, Miike R, Rice T, Wrensch M,. Reproductive factors and hormone use and risk of adult gliomas. Cancer Causes Control 2009; 20: 87-96.
12. Kabat GC, Park Y, Hollenbeck AR, Schatzkin A, Rohan TE,. Reproductive factors and exogenous hormone use and risk of adult glioma in women in the NIH-AARP Diet and Health Study. Int J Cancer 2011; 128: 944-950.
13. Michaud DS, Gallo V, Schlehofer B, Carozza SE, Miike R, Rice T, Wrensch M,. Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. Cancer Epidemiol Biomarkers Prev 2010; 19: 2562-2569.
14. IARC. A Review of Human Carcinogens. Part A: Pharmaceuticals, Vol. 100A. Lyon: International Agency for Research on Cancer, 2008; 319-331.
15. Ewertz M, Mellemkjaer L, Poulsen AH, Friis S, Sorensen HT, Pedersen L, McLaughlin JK, Olsen JH,. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 2005; 92: 1293-1297.
16. Talacchi A, Santini B, Savazzi S, Gerosa M,. Cognitive effects of tumour and surgical treatment in glioma patients. J Neurooncol 2011; 103: 541-549.
17. Gjerstorff ML,. The Danish Cancer Registry. Scan J Pub Health 2011; 39 (Suppl. 7): 42-45.
18. Storm HH, Michelsen EV, Clemmensen IH, Pihl J,. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 1997; 44: 535-539.
19. Pedersen CB,. The Danish Civil Registration System. Scan J Pub Health 2011; 39 (Suppl. 7): 22-25.
20. Kildemoes HW, Sørensen HT, Hallas J,. The Danish National Prescription Registry. Scan J Pub Health 2011; 39 (Suppl. 7): 38-41.
21. Lynge E, Sandegaard JL, Rebolj M,. The Danish National Patient Register. Scan J Pub Health 2011; 39 (Suppl. 7): 30-33.
22. Rothman K, Greenland S, Lash TL,. Modern Epidemiology, 3rd edn. Philadelphia, PA: Wolters Kluwer Health, Lippencott Williams & Wilkins, 2008.
23. WHO: WHO Collaborating Center for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2014 Oslo, 2013.
24. Jensen VM, Rasmussen AW,. Danish Education Registers. Scan J Pub Health 2011; 39 (Suppl. 7): 91-94.
25. Blenstrup LT, Knudsen LB,. Danish registers on aspects of reproduction. Scand J Public Health 2011; 39 (Suppl. 7): 79-82.
26. Chen C, Xu T, Chen J, Zhou J, Yan Y, Lu Y, Wu S,. Allergy and risk of glioma: a meta-analysis. Eur J Neurol 2011; 18: 387-395.
27. González-Agüero G, Gutiérrez AA, González-Espinosa D, Solano JD, Morales R, Gonzalez-Arenas A, Cabrera-Munoz E, Camacho-Arroyo I,. Progesterone effects on cell growth of U373 and D54 human astrocytoma cell lines. Endocrine 2007; 32: 129-135.
28. Cabrera-Muñoz E, Hernández-Hernández OT, Camacho-Arroyo I,. Role of progesterone in human astrocytomas growth. Curr Top Med Chem 2011; 11: 1663-1667.
29. Hernández-Hernández OT, González-García TK, Camacho-Arroyo I,. Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines. J Steroid Biochem Mol Biol 2012; 132: 127-134.
30. Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Varakis J,. Does sex steroid receptor status have any prognostic or predictive significance in brain astrocytic tumors? Clin Neuropathol 1998; 17: 27-34.
31. González-Agüero G, Ondarza R, Gamboa-Domínguez A,. Progesterone receptor isoforms expression pattern in human astrocytomas. Brain Res Bull 2001; 56: 43-48.
32. Sur P, Sribnick EA, Wingrave JM, Nowak MW, Ray SK, Banik NL,. Estrogen attenuates oxidative stress-induced apoptosis in C6 glial cells. Brain Res 2003; 971: 178-188.
33. Khalid MH, Shibata S, Furukawa K, Nadel A, Ammerman MD, Caputy AJ,. Role of estrogen receptor-related antigen in initiating the growth of human glioma cells. J Neurosurg 2004; 100: 923-930.
34. González-Arenas A, Hansberg-Pastor V, Hernández-Hernández OT, Gonzalez-Garcia TK, Henderson-Villalpando J, Lemus-Hernandez D, Cruz-Barrios A, Rivas-Suarez M, Camacho-Arroyo I,. Estradiol increases cell growth in human astrocytoma cell lines through ERα activation and its interaction with SRC-1 and SRC-3 coactivators. Biochim Biophys Acta 2012; 1823: 379-386.
35. Seeber B, Ziehr SC, Gschlieβer A, Moser C, Mattle V, Seger C, Griesmacher A, Concin N, Concin H, Wildt L,. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception 2012; 86: 345-359.
36. Danish Drug Manual (In Danish). Available at http://pro.medicin.dk/Laegemiddelgrupper/Grupper/149090 (last accessed 11 May 2014).
37. American College of Obstetricians and Gynecologists (ACOG). Use of Hormonal Contraception in Women with Coexisting Medical Conditions. Washington, DC: American College of Obstetricians and Gynecologists, 2006 (ACOG practice bulletin; no 73).
38. WHO. World Health Organization. 2010. Medical Eligibility Criteria for Contraceptive Use. 4. Available at http://www.who.int/reproductivehealth/publications/family-planning/9789241563888/en/index.html (last accessed 11 May 2014).
39. Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI,. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer 2010; 126: 483-489.
40. Schmidt LS, Nielsen H, Schmiedel S, Johansen C,. Social inequality and incidence of and survival from tumours of the central nervous system in a population-based study in Denmark, 1994-2003. Eur J Cancer 2008; 44: 2050-2057.
41. Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA,. Body mass index and the risk of meningioma, glioma and schwannoma in a large prospective cohort study (The HUNT Study). Br J Cancer 2013; 109: 289-294.
42. Hall K, Trussell J,. Types of combined oral contraceptives used by U.S. women. Contraception 2012; 86: 659-665.